Tags : Conducting

Pharma

Novartis Signs a Research Agreement with Target PharmaSolutions for Conducting

Shots: Novartis & Target PharmaSolutions collaborates for the onset of global TARGET-DERM study evaluating adult and pediatric patients with immune-mediated inflammatory skin conditions (IMISCs) The initial focus of the collaboration is to develop therapies & expand Novartis’ footprints in immune-dermatology for atopic dermatitis (eczema) with further expansion to hidradenitis suppurativa (painful bumps under the skin), […]Read More